603858 步长制药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)2.0212.660-11.4768.29713.610
总资产报酬率 ROA (%)1.1121.489-6.6794.9728.445
投入资产回报率 ROIC (%)1.4912.021-8.8796.48310.386

边际利润分析
销售毛利率 (%)57.00768.15271.69173.78176.628
营业利润率 (%)7.5413.292-8.35710.28114.777
息税前利润/营业总收入 (%)8.5313.671-7.66410.95815.486
净利润/营业总收入 (%)3.3351.147-10.6417.03111.515

收益指标分析
经营活动净收益/利润总额(%)90.836258.509-135.174101.88991.822
价值变动净收益/利润总额(%)0.0674.799-0.217-2.6720.662
营业外收支净额/利润总额(%)-1.388-10.5090.788-2.143-0.198

偿债能力分析
流动比率 (X)1.2811.2081.2921.1661.022
速动比率 (X)0.5240.4890.7470.6310.668
资产负债率 (%)46.92145.54944.08239.96739.654
带息债务/全部投入资本 (%)24.71720.70520.11719.062--
股东权益/带息债务 (%)291.316365.294379.042411.068397.511
股东权益/负债合计 (%)116.047122.075127.755149.940151.118
利息保障倍数 (X)7.8035.304-10.09312.27820.982

营运能力分析
应收账款周转天数 (天)42.89842.50037.21432.1390.000
存货周转天数 (天)375.006372.069324.192287.4930.000